- Home
- DVS vs BWAY Comparison
DVS vs BWAY Comparison
Compare DVS & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVS
- BWAY
- Stock Information
- Founded
- DVS 2011
- BWAY 2003
- Country
- DVS Canada
- BWAY Israel
- Employees
- DVS N/A
- BWAY N/A
- Industry
- DVS
- BWAY Medical/Dental Instruments
- Sector
- DVS
- BWAY Health Care
- Exchange
- DVS Nasdaq
- BWAY Nasdaq
- Market Cap
- DVS 210.3M
- BWAY 207.4M
- IPO Year
- DVS N/A
- BWAY 2019
- Fundamental
- Price
- DVS $2.74
- BWAY $8.88
- Analyst Decision
- DVS
- BWAY Strong Buy
- Analyst Count
- DVS 0
- BWAY 3
- Target Price
- DVS N/A
- BWAY $13.17
- AVG Volume (30 Days)
- DVS 312.6K
- BWAY 24.2K
- Earning Date
- DVS 05-23-2025
- BWAY 05-13-2025
- Dividend Yield
- DVS N/A
- BWAY N/A
- EPS Growth
- DVS N/A
- BWAY N/A
- EPS
- DVS N/A
- BWAY 0.06
- Revenue
- DVS N/A
- BWAY $41,016,000.00
- Revenue This Year
- DVS N/A
- BWAY $351.53
- Revenue Next Year
- DVS N/A
- BWAY $21.84
- P/E Ratio
- DVS N/A
- BWAY $56.55
- Revenue Growth
- DVS N/A
- BWAY 29.04
- 52 Week Low
- DVS $0.60
- BWAY $5.13
- 52 Week High
- DVS $3.00
- BWAY $11.79
- Technical
- Relative Strength Index (RSI)
- DVS N/A
- BWAY 49.99
- Support Level
- DVS N/A
- BWAY $8.61
- Resistance Level
- DVS N/A
- BWAY $9.28
- Average True Range (ATR)
- DVS 0.00
- BWAY 0.41
- MACD
- DVS 0.00
- BWAY 0.06
- Stochastic Oscillator
- DVS 0.00
- BWAY 72.22
About DVS Dolly Varden Silver Corporation Common Shares
Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.